These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026?

Core Viewpoint - The technology sector has driven market gains this year, while the healthcare industry has lagged, although some healthcare stocks have shown strong performance [1][2]. Group 1: CRISPR Therapeutics - CRISPR Therapeutics has seen a significant rise in stock price, increasing by 44% this year, driven by clinical and regulatory progress in its pipeline [2][4]. - The company is developing CTX310, a potential one-time treatment for lowering LDL cholesterol and triglycerides, which could be a breakthrough in cardiovascular health [5][6]. - Despite being unprofitable and generating minimal revenue, CRISPR Therapeutics has potential upside due to progress in its pipeline and expectations for commercial success with its approved product, Casgevy [8][9]. Group 2: HCA Healthcare - HCA Healthcare has outperformed the market with a stock increase of 58% this year, supported by strong financial results and recognition as one of the top hospital chains [2][10]. - The company is trading at a forward price-to-earnings ratio of 16, which is below the healthcare sector average of 18.2, indicating potential value [11][12]. - There are uncertainties regarding federal policy changes that could impact patient demand for HCA's services, but the company maintains a strong competitive edge and is well-positioned for long-term growth [13][16].